Methods of treating systemic sclerosis and idiopathic pulmonary fibrosis
AssigneeHorizon Therapeutics Ireland DAC
InventorsFarah Naseer ALI, Paul PELOSO
Life of this patent
Estimating the term…
Abstract
Described herein are uses of crystalline forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid in the treatment of diseases or conditions that would benefit by administration with an LPA1 receptor antagonist compound.
Claims30
A method of treating systemic sclerosis or lung disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I), or a pharmaceutically acceptable salt thereof, wherein Compound I, or a pharmaceutically acceptable salt thereof, is administered at a daily dose equivalent to at least about 300 mg/day of Compound I.
(canceled)
-11. (canceled)
13-22. (canceled)
(canceled)
(canceled)
30-39. (canceled)
(canceled)
(canceled)
(canceled)
A method of treating systemic sclerosis or lung disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I), or a pharmaceutically acceptable salt thereof, wherein Compound I, or a pharmaceutically acceptable salt thereof, is administered orally in the form of a solid form pharmaceutical composition once or twice daily with a meal.
Dependencies are inferred from the claim text.